BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chao D, Botwin GJ, Morgan TR. Update on Recently Approved Treatments for Hepatitis C. Curr Treat Options Gastro 2014;12:211-28. [DOI: 10.1007/s11938-014-0013-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Xu F, Leidner AJ, Tong X, Holmberg SD. Estimating the Number of Patients Infected With Chronic HCV in the United States Who Meet Highest or High-Priority Treatment Criteria. Am J Public Health 2015;105:1285-9. [PMID: 25973816 DOI: 10.2105/AJPH.2015.302652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
2 Rossi LM, Escobar-Gutierrez A, Rahal P. Advanced molecular surveillance of hepatitis C virus. Viruses 2015;7:1153-88. [PMID: 25781918 DOI: 10.3390/v7031153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Prieto Ortíz JE, Sánchez Pardo S, Rojas Díaz EL, Huertas Pacheco SJ. Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. Rev Colomb Gastroenterol 2014;29:424-32. [DOI: 10.22516/25007440.440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Huang MH, Jiang JD, Peng ZG. Recent advances in the anti-HCV mechanisms of interferon. Acta Pharmaceutica Sinica B. 2014;4:241-247. [PMID: 26579391 DOI: 10.1016/j.apsb.2014.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
5 El-Kamary SS, Hashem M, Saleh DA, Ehab M, Sharaf SA, El-Mougy F, Abdelsalam L, Jhaveri R, Aboulnasr A, El-Ghazaly H. Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. J Infect. 2015;70:512-519. [PMID: 25623176 DOI: 10.1016/j.jinf.2015.01.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
6 Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, Teshale EH, Spradling PR, Boscarino JA, Trinacty CM, Schmidt MA, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Tong X, Xu F, Gordon SC, Nerenz DR, Lu M, Lamerato L, Wang Y, Rupp LB, Akkerman N, Oja-Tebbe N, Zhang T, Li J, Sitarik A, Larkin D, Boscarino JA, Daar ZS, Curry PJ, Smith RE, Vijayadeva V, Parker JV, Schmidt MA, Donald JL, Keast EM. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. Clin Infect Dis. 2016;62:289-297. [PMID: 26417034 DOI: 10.1093/cid/civ860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
7 Helmers RA, Byrne TJ, Wesselius LJ, Leslie KO. Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient. Mayo Clin Proc 2015;90:1294-7. [PMID: 26231293 DOI: 10.1016/j.mayocp.2015.06.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]